Drug intelligence / Profile preview

MVX-200 Series

Development stage: Preclinical
Lead developer: MaveriX Oncology
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

MVX-200 is a series of conditionally activated small molecule drug conjugates (CA-SMDCs) being developed by MaveriX Oncology. These compounds are designed to deliver a Toll-like receptor 7/8 (TLR7/8) agonist payload specifically to the tumor microenvironment. By utilizing a conditional activation mechanism, the drug aims to stimulate innate immune signaling within tumors while minimizing systemic toxicity typically associated with TLR agonists. The program is currently in the discovery stage for the treatment of undisclosed cancers.

Targets

TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)

Beyond the preview

Go deeper on MVX-200 Series.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVX-200 Series.